Listing of Claims:

1-83 (canceled).

- 84. (Previously presented) A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:
- a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:

$$[H_2N-A-CO]_a-S$$
 (Formula I)

wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is >= 2, and represents the number of fully side-chain protected peptide sequences on the resin support;

- b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;
- c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being

Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:

R(COOH)₂, (Formula II)

wherein R represents a $N(X)(CH_2-)_2$, NH(X)CH<, $CH_2<$, $NH(X)CH(CH_2-)_2$ or $CH_2(CH_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:

 $[H_2N-A-CO]_{a-b}$

> S

[HOOC-R-CO-HN-A-CO]_b, (Formula III)

wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:

CO-HN-A-CO

R< >S

CO-HN-A-CO , (Formula IV)

and

e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;

Serial No. 10/724,233

Atty. Docket No.: P63882US1

f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:

CO-HN-A-CO-Y

R<

CO-HN-A-CO-Y ,

(Formula V),

wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH_2 .

- 85. (Previously presented) A method according to claim 84 further comprising the steps of prior to step (f)
- (e') splitting of any N-terminal Fmoc, Boc or Aloc group originating from the dicarboxylic acid used in step (c) and (e'') continuing the solid phase synthesis so as to provide a compound of the following formula:

CO-HN-A-CO

 $H_2N-B-CO-R' <$

>S

CO-HN-A-CO

(Formula VI)

wherein B represents a peptide sequence, and R' represents a $N(CH_2-)_2$, NHCH<, or NHCH($CH_2-)_2$ group.

- 86. (Previously presented) The method according to claim 84, wherein the achiral acid is imino diacetic acid.
- 87. (Currently amended) The method according to claim 84 91, wherein the peptide sequences are derived from OspC protein of Borrelia burgdorferi.

- 88. (Currently amended) The method according to claim 84 91 for preparing an LPA for presenting two identical C-terminal sequences Pro-Lys-Lys-Pro (Seq. ID 7) of OspC.
- 89. (Currently amended) The method according to claim 84 91, wherein the peptide sequences are derived from the flagellum of Borrelia burgdorferi.
- 90. (Currently amended) The method according to claim 84 91 for preparing an LPA selected from the group consisting of

[LPA-I]: FmocN(CH₂CO-ProValValAlaGluSerProLysLysPro-OH)₂ (FmocN(CH₂CO-Seq. ID 1-OH)₂)

[LPA-III]: NH₂CH(CH₂CO-ProValValAlaGluSerProLysLysPro-OH)₂ (NH₂CH(CH₂CO-Seq. ID 1-OH)₂

[LPA-VII]: $CH_2(CH2CO-\beta-Ala-\beta-Ala-\beta-Ala)_2$ ($CH_2(CH_2CO-\beta-Ala-\beta-Ala-Seq.$ ID $4-\beta-Ala-OH)_2$)

[LPA-VIII]: H_2C (C H_2CO -LysGluProAsnLysGlyValAsnProAspGluVal β Ala) $_2$ COOH (H_2C (C H_2CO -Seq. ID $4-\beta$ -Ala) $_2$ COOH),

[LPA-IX]: Fmoc-NHCH(CH₂CO-AspArgValTyrIleHisProPheHisLeu-NH₂)₂ (Fmoc-NHCH(CH₂CO-Seq. ID $5-NH_2$)₂),

[LPA-X]: Aloc-NHCH(CH₂CO-AspArgValTyrIleHisProPheHisLeu-NH₂)₂ (Aloc-NHCH(CH₂CO-Seq. ID $5-NH_2$)₂), and

- 91. (Previously presented) A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences from Borrelia burgdorferi having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:
- a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:

$$[H_2N-A-CO]_a-S$$
 , (Formula I)

wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is >= 2, and represents the number of fully side-chain protected peptide sequences on the resin support;

- b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;
- c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:

wherein R represents a $N(X)(CH_2-)_2$, NH(X)CH<, $CH_2<$, $NH(X)CH(CH_2-)_2$ or $CH_2(CH_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:

 $[H_2N-A-CO]_{a-b}$

> S

[HOOC-R-CO-HN-A-CO]_b, (Formula III)

wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:

CO-HN-A-CO

R< >S

CO-HN-A-CO , (Formula IV)

and

- e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;
- f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:

CO-HN-A-CO-Y

R<

CO-HN-A-CO-Y , (Formula V),

wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH_2 .

- 92. (Previously presented) A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences derived from OspC protein of Borrelia burgdorferi having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:
- a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:

$$[H_2N-A-CO]_a-S$$
 , (Formula I)

wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is >= 2, and represents the number of fully side-chain protected peptide sequences on the resin support;

- b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;
- c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being

Ċ.

Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:

R(COOH)₂, (Formula II)

wherein R represents a N(X) (CH_2 -)₂, NH(X) CH_2 -, CH_2 -, NH(X) $CH(CH_2$ -)₂ or $CH_2(CH_2$ -)₂ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:

 $[H_2N-A-CO]_{a-b}$

> S

[HOOC-R-CO-HN-A-CO]_b, (Formula III)

wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:

CO-HN-A-CO

R< >S

CO-HN-A-CO , (Formula IV)

and

e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;

f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:

CO-HN-A-CO-Y

R<

CO-HN-A-CO-Y ,

(Formula V),

wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH_2 .

- 93. (Previously presented) A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences from the flagellum of Borrelia burgdorferi having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:
- a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:

$$[H_2N-A-CO]_a-S$$
 , (Formula I)

wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring Lamino acid residues, and a is >= 2, and represents the number of fully side-chain protected peptide sequences on the resin support;

b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;

c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:

 $R(COOH)_2$, (Formula II)

wherein R represents a $N(X)(CH_2-)_2$, NH(X)CH<, $CH_2<$, $NH(X)CH(CH_2-)_2$ or $CH_2(CH_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:

 $[H_2N-A-CO]_{a-b}$

> S

[HOOC-R-CO-HN-A-CO]_b, (Formula III)

wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:

CO-HN-A-CO

R< >S

CO-HN-A-CO , (Formula IV)

and

- e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;
- f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:

CO-HN-A-CO-Y

R<

CO-HN-A-CO-Y ,

(Formula V),

wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH_2 .

94. (Withdrawn) A ligand presenting assembly (LPA) having a formula selected from the group consisting of

CH2-CO-NH-A-CO-Y

(1) HN<

CH2-CO-NH-A-CO-Y

CH2-CO-NH-A-CO-Y

(2) $H_2N-HC<$

CH2-CO-NH-A-CO-Y

CH2-CO-NH-A-CO-Y

(3) $H_2C<$

CH2-CO-NH-A-CO-Y

CO-NH-A-CO-Y

(4) $H_2N-CH<$

CO-NH-A-CO-Y

or

CO-NH-A-CO-Y

(5) CH₂<

CO-NH-A-CO-Y

obtained by the method of claim 84, wherein A represents a peptide sequence having between 4 and 20 naturally occurring amino acid residues, and wherein Y represents OH or NH_2 .

95. (Withdrawn) The method according to claim 85 for preparing an LPA selected from the group consisting of

[LPA-IV]: H-Lys-NHCH(CH₂CO-ProValValAlaGluSerProLysLysPro-OH)₂ (H-Lys-HNCH(CH2CO-Seq. ID 1-OH)₂

[LPA-XI]: Fmoc-AspProThrGlnAsnIleProProGly-NHCH(CH₂CO-AspArgValTyrlleHisProPheHisLeu-NH₂)₂ (Fmoc-Seq. ID 6-NHCH(CH₂CO-Seq. ID 5-NH₂)₂).